197 related articles for article (PubMed ID: 31124341)
1. Factors Associated with Adherence to Allergen Specific Subcutaneous Immunotherapy.
Lee JH; Lee SH; Ban GY; Ye YM; Nahm DH; Park HS; Shin YS
Yonsei Med J; 2019 Jun; 60(6):570-577. PubMed ID: 31124341
[TBL] [Abstract][Full Text] [Related]
2. A 10-year experience of a novel and safe modified environmental rush immunotherapy protocol.
Fajt ML; Rosenberg SL; Yecies E; Traister RS; Petrov AA
Allergy Asthma Proc; 2017 Jul; 38(4):309-316. PubMed ID: 28668111
[TBL] [Abstract][Full Text] [Related]
3. Clinical Efficacy of Allergen-Specific Immunotherapy from Patient and Physician Perspectives.
Shin YS; Jung JW; Park JW; Choi JH; Kwon JW; Lee S; Kim JH; Lee SM; Ahn YM; Han MY;
Yonsei Med J; 2019 May; 60(5):446-453. PubMed ID: 31016906
[TBL] [Abstract][Full Text] [Related]
4. Risk factors and strategies in nonadherence with subcutaneous immunotherapy: a real-life study.
Yang Y; Wang Y; Yang L; Wang J; Huang N; Wang X; Hu L; Jiang Q; Liu G; Zhu R
Int Forum Allergy Rhinol; 2018 Nov; 8(11):1267-1273. PubMed ID: 30048045
[TBL] [Abstract][Full Text] [Related]
5. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy.
Kiel MA; Röder E; Gerth van Wijk R; Al MJ; Hop WC; Rutten-van Mölken MP
J Allergy Clin Immunol; 2013 Aug; 132(2):353-60.e2. PubMed ID: 23651609
[TBL] [Abstract][Full Text] [Related]
6. Early Intervention Improves Clinical Responses to House Dust Mite Immunotherapy in Allergic Rhinitis Patients.
Qi S; Chen H; Huang N; Li W; Liu G; Wang Y; Hu L; Wang X; Zhang W; Zhu R
Int Arch Allergy Immunol; 2016; 171(3-4):234-240. PubMed ID: 28049194
[TBL] [Abstract][Full Text] [Related]
7. Safety and Utility of Rush Immunotherapy with Aqueous Allergen Extracts for Treatment of Respiratory Allergies.
Lee JH; Choi JH; Jeong KB; Lee SJ; Lee MK; Lee WY; Yong SJ; Kim SH
J Korean Med Sci; 2021 Jan; 36(3):e18. PubMed ID: 33463092
[TBL] [Abstract][Full Text] [Related]
8. Safety of immunotherapy in patients with rhinitis, asthma or atopic dermatitis using an ultra-rush buildup. A retrospective study.
Cardona R; Lopez E; Beltrán J; Sánchez J
Allergol Immunopathol (Madr); 2014; 42(2):90-5. PubMed ID: 23265265
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous and Sublingual Immunotherapy in a Mouse Model of Allergic Asthma.
Hesse L; Nawijn MC
Methods Mol Biol; 2017; 1559():137-168. PubMed ID: 28063043
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of pollen allergoid tyrosine-adsorbed subcutaneous immunotherapy on allergic rhinitis and asthma.
Vogelberg C; Klimek L; Kruppert S; Becker S
Clin Exp Allergy; 2024 Apr; 54(4):253-264. PubMed ID: 38146840
[TBL] [Abstract][Full Text] [Related]
11. European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a real-life clinical assessment.
Calderón MA; Vidal C; Rodríguez Del Río P; Just J; Pfaar O; Tabar AI; Sánchez-Machín I; Bubel P; Borja J; Eberle P; Reiber R; Bouvier M; Lepelliez A; Klimek L; Demoly P;
Allergy; 2017 Mar; 72(3):462-472. PubMed ID: 27718250
[TBL] [Abstract][Full Text] [Related]
12. Allergen immunotherapy: an update on protocols of administration.
Larenas-Linnemann D
Curr Opin Allergy Clin Immunol; 2015 Dec; 15(6):556-67. PubMed ID: 26485100
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors for clinical response to allergy immunotherapy in children with asthma and rhinitis.
Li Q; Li M; Yue W; Zhou J; Li R; Lin J; Li Y
Int Arch Allergy Immunol; 2014; 164(3):210-7. PubMed ID: 25138246
[TBL] [Abstract][Full Text] [Related]
14. Sensitization to common allergens and its association with allergic disorders at age 4 years: a whole population birth cohort study.
Arshad SH; Tariq SM; Matthews S; Hakim E
Pediatrics; 2001 Aug; 108(2):E33. PubMed ID: 11483843
[TBL] [Abstract][Full Text] [Related]
15. Non-adherence to subcutaneous allergen immunotherapy: inadequate health insurance coverage is the leading cause.
Vaswani R; Garg A; Parikh L; Vaswani S
Ann Allergy Asthma Immunol; 2015 Sep; 115(3):241-3. PubMed ID: 26195439
[TBL] [Abstract][Full Text] [Related]
16. Is There Any Parameter Helpful for Predicting a Suitable Candidate for Mite Immunotherapy?
Karaman S; Can D; Erdem SB; Nacaroğlu HT; Karkıner CŞ; Günay İ
Iran J Allergy Asthma Immunol; 2016 Apr; 15(2):105-11. PubMed ID: 27090363
[TBL] [Abstract][Full Text] [Related]
17. Patient initiation and persistence with allergen immunotherapy.
Anolik R; Schwartz AM; Sajjan S; Allen-Ramey F
Ann Allergy Asthma Immunol; 2014 Jul; 113(1):101-7. PubMed ID: 24814759
[TBL] [Abstract][Full Text] [Related]
18. Patient selection for subcutaneous versus sublingual immunotherapy.
Larenas-Linnemann D
Curr Opin Allergy Clin Immunol; 2015 Dec; 15(6):588-95. PubMed ID: 26485098
[TBL] [Abstract][Full Text] [Related]
19. [Preventive immunotherapy].
Boquete M; Carballada F; Expósito F; González A
Allergol Immunopathol (Madr); 2000; 28(3):89-93. PubMed ID: 10867376
[TBL] [Abstract][Full Text] [Related]
20. Different Responses in Induction of Allergen Specific Immunoglobulin G4 and IgE-Blocking Factors for Three Mite Subcutaneous Immunotherapy Products.
Park KH; Lee SC; Son YW; Jeong KY; Shin YS; Shin JU; Sim da W; Park HJ; Lee JH; Lee KH; Park JW
Yonsei Med J; 2016 Nov; 57(6):1427-34. PubMed ID: 27593871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
